Patho-
physiology

EPP & XLP are rare genetic disorders of the heme biosynthetic pathway1

The porphyrias are a group of lifelong metabolic disorders, each resulting from a defect in 1 of 8 enzymes involved in heme synthesis. Porphyrias can be broadly classified as acute or cutaneous, depending on the predominant clinical features.2

Erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) are cutaneous porphyrias caused by defects in either the final enzyme (FECH) or first enzyme (ALAS2) of heme synthesis, respectively. Both disorders are primarily characterized by painful cutaneous phototoxicity after light exposure, usually beginning in infancy or early childhood.1,3

Globe icon

Estimated global prevalence4,5
1:57,000 to 1:200,000

More recent data using a biomedical database found a prevalence estimating 1:17,000.1
Globe icon

Estimated US prevalence6
~6,000 patients
with EPP

XLP accounts for
approximately 10% of
these cases.3
frame-textframe-text

Both EPP and XLP lead to the accumulation of protoporphyrin IX (PPIX), causing the characteristic phototoxicity in addition to other systemic complications that can develop.1

PPIX buildup in the liver can cause hepatobiliary dysfunction and damage9,10

PPIX accumulation in hepatocytes and bile canaliculi lies at the core of hepatobiliary complications in EPP and XLP11

No icon

PPIX deposition and biliary obstruction9,10

Excess PPIX is excreted by the liver into bile, where it becomes insoluble and can crystallize, forming stones and obstructing bile flow.  

Three circular arrows icon

Escalating hepatobiliary dysfunction3,10 

Biliary obstruction impairs PPIX excretion, resulting in further PPIX accumulation and escalating PPIX-mediated liver damage.    

Liver icon

PPIX-induced liver damage9

Ultrastructural liver damage in hepatocyte nuclei, endoplasmic reticulum, and plasma membranes is an early and consistent finding in EPP and XLP, even in patients without clinically evident liver dysfunction.  

frame-textframe-text
PPIX-mediated liver dysfunction has been reported in over 50% of patients with EPP and XLP, which may progress to liver failure in up to 5% of patients.10,12